Phuong A. Nguyen

Moderna Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

8h-index237citations55works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune cells in cancer(24), Glycosylation and Glycoproteins Research(19), Phagocytosis and Immune Regulation(15), Ubiquitin and proteasome pathways(14), Immunotherapy and Immune Responses(9)

Publications54 total

A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial
Nature Medicine·2026Open Access
1318 Phase 1 clinical data show FX-909, a first-in-class oral PPARG inhibitor, drives immune modulation and pro-inflammatory cytokine induction in IO-experienced patients with advanced urothelial carcinoma
2025Open Access
Abstract 2966: The anti-tumor activity of a novel anti-Her2 and anti-c-Met bispecific antibody-drug conjugate
Cancer Research·2025· 1 cited
1426 The anti-tumor activity of a novel anti-Her2/anti-Trop2 bispecific VHH antibody-drug conjugate (ADC)
Regular and Young Investigator Award Abstracts·2024Open Access
Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth
Cancers·2024Open Access
Antibodies Targeting Human or Mouse VSIG4 Repolarize Tumor-Associated Macrophages Providing the Potential of Potent and Specific Clinical Anti-Tumor Response Induced across Multiple Cancer Types
International Journal of Molecular Sciences·2024· 11 citedOpen Access
Abstract 5627: PPARG-high circulating monocytes exhibit an immunosuppressive phenotype in urothelial cancer patients treated with anti-PD1
Cancer Research·2024
Supplementary Figure 3 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
Supplementary Figure 4 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
FIGURE 6 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
Supplementary Figure 4 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
Data from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
FIGURE 1 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
Data from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023· 1 citedOpen Access
Supplementary Figure 3 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
Supplementary Figure 8 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
FIGURE 3 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
FIGURE 3 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
Supplementary Figure 7 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
Supplementary Table 1 from PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Mohammad Zafari(38), Ryan Phennicie(38), Denise Manfra(38), Igor Feldman(38), Tatiana I. Novobrantseva(38), Kevin Kauffman(37), Dominika Nowakowska(37), Michael A. Brehm(37), Brian O’Nuallain(36), Sara Basinski(36), Veronica Komoroski(36), Elisabeth H. Vollmann(35), Kate Rooney(35), Elizabeth K. Culyba(35), Joseph Wahle(35), Carola H. Ries(35), Steve Sazinsky(35), Aimée M. Deaton(4), Paul Nioi(4), Lucas D. Ward(4)